May 7th 2024
In an interview with Targeted Oncology, Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
KCd Regimen Does Not Show Non-Inferiority to Autologous HSCT in Multiple Myeloma
January 7th 2023While upfront transplant showed benefit vs carfilzomib, cyclophosphamide, and dexamethasone in the phase 2 CARDAMON study of patients with multiple myeloma, 57.7% of patients achieved at least a very good partial response with the combination.
Read More
Allogeneic SCT Shows Efficacy in TP53+ AML and MDS
December 15th 2022Melhem M. Solh, MD, discusses results of a study investigating allogeneic stem cell transplant in patients with myelodysplastic syndrome and acute myeloid leukemia with a TP53 mutation, previously presented at the 2022 Transplantation & Cellular Therapy Meetings.
Watch
Ten-Year Omidubicel Data Improves Survival in Hematologic Malignancies With HSCT
November 28th 2022Favorable long-term survival rates and manageable rates of graft-vs-host disease were elicited with omidubicel in patients with hematologic malignancies who underwent allogeneic stem cell transplant.
Read More
Best Uses of Transplantation for Patients With Peripheral T-Cell Lymphoma
November 15th 2022Randomized studies examining patients with peripheral T-cell lymphoma regarding the role of transplant are lacking and more research is needed to personalize therapy for patients based on subtype, biomarkers, mutational profiling, and radiographic parameters.
Read More
Ponatinib/Blinatumomab Displays Efficacy as a Chemo-Free, HSCT-Sparing Option in Ph+ ALL
September 28th 2022In an interview before the conference, Fadi G. Haddad, MD, discussed the updated results from the combination of blinatumomab and ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Read More
Guidelines Needed for Monitoring Pulmonary Complications After Pediatric HSCT
August 12th 2022Several priority areas need to be examined in future research to improve the quality of clinical guidelines to address when and how to monitor pediatric hematopoietic stem cell transplant survivors.
Read More
Omidubicel Developer Seeks FDA Approval to Treat Blood Cancers in Need of Transplantation
June 3rd 2022Within 60 days, the FDA will make a decision on whether to accept the biologics license application for omidubicel as treatment for patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant.
Read More
Stem Cell Transplant Holds its Position as Upfront Treatment for Hematologic Malignancies
May 10th 2022In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed the evolving role of stem cell transplant in hematologic malignancies as CAR T-cell therapies begin to reshape treatment landscapes.
Read More